Panbela Therapeutics, Moffitt Cancer Center Testing Immunotherapy Enhancer in STK11-Mutant NSCLC
The partners will evaluate Panbela's eflornithine with Merck's Keytruda in a Phase I/II trial as proof of concept for modulating the immune system using polyamines and standard therapies.
Cofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain Spinout
Culmination Bio's 4.5 million biospecimens and longitudinal omics and clinical data may help Cofactor rapidly advance the OncoPrism assay into multiple cancer types.
NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC
The agency estimated that the drug combination's cost-effectiveness falls within what it considers an acceptable use of the NHS's resources.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
Merck's Keytruda Sales Grow 20 Percent in Q1 While Overall Revenues Dip 9 Percent
The firm's blockbuster immunotherapy was once again its main growth driver during the first quarter of 2023 as Merck continued expanding its indications.